EUVIMEDEUVIMED entdecken
Crossref

Letter to the Editor: Lianhe Xiaozhi ointment for metabolic dysfunction-associated steatotic liver disease - a gut-liver-brain axis perspective

Tian-Ci Tang, Rui-Xi Ming, Yu-Meng Liu, Bin Li

World Journal of Gastroenterology · 28.08.2026 · 32 (32)

DOI: 10.3748/wjg.118636 ↗

Kurz gefasst

Fachartikel in der Zeitschrift World Journal of Gastroenterology, online erschienen am 28.08.2026. Verfasst von Tian-Ci Tang und 3 weiteren Autor:innen. Die Arbeit nennt 12 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly nonalcoholic fatty liver disease, is a growing global health burden with limited approved therapies. In a recent article published in the World Journal of Gas troenterology , Nie et al reported that Lianhe Xiaozhi ointment (LXO)—a patented traditional Chinese medicine (TCM) formulation derived from Huanglian Wendan decoction—markedly ameliorates MASLD in high-fat diet models through activation of the peroxisome proliferator-activated receptor alpha (PPARα) pathway. This letter commends the comprehensive multi-omics and in vivo approach of Nie et al , emphasizes its concordance with prior findings on PPARα’s central role in hepatic lipid metabolism, and discusses how LXO’s gut microbiota-PPARα-inflammation axis introduces a novel therapeutic dimension for MASLD. We provide a comparative analysis of LXO’s effects vs established MASLD interventions, noting concordant improvements in weight gain, metabolic indices, liver injury, and inflammation. We also offer a constructive critique of the study’s limitations, including the need for causal validation (e.g., Ppara knockout models) and translational investigation (bioactive compound pharmacokinetics and human trials). Finally, we expand on mechanistic hypotheses suggested by the authors, proposing exploration of the gut-liver-brain axis and associated neuroimmune outcomes in MASLD and outlining future research directions such as PPARα-targeted validation, serum pharmacochemistry, and neuroinflammatory profiling. This commentary affirms the hypothesis-defining and field-advancing significance of Nie et al ’s work, demonstrating how integrating TCM insights with cutting-edge mechanistic studies can drive innovative MASLD therapies.

Zitieren

APA

Tang, T., Ming, R., Liu, Y., & Li, B. (2026). Letter to the Editor: Lianhe Xiaozhi ointment for metabolic dysfunction-associated steatotic liver disease - a gut-liver-brain axis perspective. World Journal of Gastroenterology, 32(32). https://doi.org/10.3748/wjg.118636

Vancouver

Tang T, Ming R, Liu Y, Li B. Letter to the Editor: Lianhe Xiaozhi ointment for metabolic dysfunction-associated steatotic liver disease - a gut-liver-brain axis perspective. World Journal of Gastroenterology. 2026;32(32). doi:10.3748/wjg.118636

BibTeX
@article{Tang2026,
  author = {Tang, Tian-Ci and Ming, Rui-Xi and Liu, Yu-Meng and Li, Bin},
  title = {Letter to the Editor: Lianhe Xiaozhi ointment for metabolic dysfunction-associated steatotic liver disease - a gut-liver-brain axis perspective},
  journal = {World Journal of Gastroenterology},
  year = {2026},
  volume = {32},
  number = {32},
  doi = {10.3748/wjg.118636}
}
Kostenlos starten →